These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19963607)

  • 1. Enhancement of the immune response to chronic myeloid leukaemia via controlled treatment scheduling.
    Chang H; Astolfi A
    Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():3889-92. PubMed ID: 19963607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining pharmacological therapy and vaccination in Chronic Myeloid Leukemia via model predictive control.
    Laurino M; Stano M; Betta M; Pannocchia G; Landi A
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():3925-8. PubMed ID: 24110590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
    Valent P
    Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
    Rojas JM; Knight K; Wang L; Clark RE
    Leukemia; 2007 Nov; 21(11):2287-95. PubMed ID: 17637811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
    Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
    J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
    Breccia M; Bocchia M; Cannella L; Defina M; Ippoliti M; Loglisci G; Santopietro M; Lauria F; Alimena G
    Br J Haematol; 2010 Jul; 150(2):240-2. PubMed ID: 20346015
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
    Dufva IH; Karle H; Brondum-Nielsen K; Andersen MK; Madsen HO; Johnsen HE
    Leukemia; 2005 Apr; 19(4):671-3. PubMed ID: 15703782
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
    Westers TM; van den Ancker W; Bontkes HJ; Janssen JJ; van de Loosdrecht AA; Ossenkoppele GJ
    Immunotherapy; 2011 Apr; 3(4):569-76. PubMed ID: 21463196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia.
    Coleman S; Fisher J; Hoy T; Burnett AK; Lim SH
    Leukemia; 1996 Mar; 10(3):483-7. PubMed ID: 8642866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
    Nanda S; Moore H; Lenhart S
    Math Biosci; 2007 Nov; 210(1):143-56. PubMed ID: 17599363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.
    Guarini A; Breccia M; Montefusco E; Petti MC; Zepparoni A; Vitale A; Foa R
    Br J Haematol; 2001 Apr; 113(1):136-42. PubMed ID: 11328293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
    Eisendle K; Wolf D; Gastl G; Kircher-Eibl B
    Leuk Lymphoma; 2005 May; 46(5):663-70. PubMed ID: 16019503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses to chronic myeloid leukaemia.
    Barrett A; Jiang YZ
    Bone Marrow Transplant; 1992 May; 9(5):305-11. PubMed ID: 1617313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
    El Missiry M; Adnan Awad S; Rajala HL; Al-Samadi A; Ekblom M; Markevän B; Åstrand-Grundström I; Wold M; Svedahl ER; Juhl BR; Bjerrum OW; Haulin I; Porkka K; Olsson-Strömberg U; Hjorth-Hansen H; Mustjoki S
    J Cancer Res Clin Oncol; 2016 May; 142(5):1041-50. PubMed ID: 26746653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia.
    Ghosn Y; Kamareddine MH; Tawk A; Elia C; El Mahmoud A; Terro K; El Harake N; El-Baba B; Makdessi J; Farhat S
    Technol Cancer Res Treat; 2019; 18():1533033819853241. PubMed ID: 31138064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine enhancement of immunogenicity in chronic myeloid leukaemia.
    Coleman S; Throp D; Fisher J; Bailey-Wood R; Lim SH
    Leukemia; 1997 Dec; 11(12):2055-9. PubMed ID: 9447820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine development for chronic myelogenous leukaemia.
    Wong KK; Chatterjee S
    Lancet; 2005 Feb 19-25; 365(9460):631-2. PubMed ID: 15721455
    [No Abstract]   [Full Text] [Related]  

  • 20. T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
    Westermann J; Schlimper C; Richter G; Mohm J; Dörken B; Pezzutto A
    Br J Haematol; 2004 Apr; 125(2):213-6. PubMed ID: 15059144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.